Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | STS | P08842 | 1/20 | 0.52 |
| ▸ | TNKS | O95271 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | PARP1 | P09874 | 4/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.51 |
| ▸ | GABRP | O00591 | 2/20 | 0.51 |
| ▸ | GABRD | O14764 | 2/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11298351 | 0.83 | TNKS (0.53) | TNKSNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL28490130 | 0.83 | TNKS (0.50) | TNKSNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL29854946 | 0.81 | HPGD (0.59) | TNKSNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3662695 | 0.81 | HPGD (0.59) | TNKSNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL23334588 | 0.79 | MAPT (0.73) | ALOX15STSNPC1HPGDRAB9A | |
| SCHEMBL11291776 | 0.77 | TNKS (0.47) | TNKSNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL8493156 | 0.77 | ALOX15 (0.66) | ALOX15TNKSHPGDSMN1; SMN2PARP1 | |
| SCHEMBL25412346 | 0.77 | ALOX15 (0.57) | ALOX15STSNPC1HPGDRAB9A | |
| SCHEMBL7574697 | 0.77 | ALOX15 (0.66) | ALOX15STSNPC1HPGDRAB9A | |
| SCHEMBL2572848 | 0.77 | TNKS (0.44) | TNKSNPC1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ATHENEX, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ATHENEX, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230266513-A1 | OPTICAL FILTER | AGC Inc. (JP) | 2023-08-24 | — | — | US | disclosed |
| WO-2022075291-A1 | OPTICAL FILTER | ＡＧＣ株式会社 | 2022-04-14 | — | — | WO | disclosed |
| US-20220106312-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | Health Hope Pharma Limited (HK) | 2022-04-07 | — | — | US | disclosed |
| WO-2021085372-A1 | RESIN COMPOSITION, COMPOUND (Z), OPTICAL FILTER, AND USE THEREOF | JSR株式会社 | 2021-05-06 | — | — | WO | disclosed |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-20110045397-A1 | CHARGE CONTROL AGENT AND RELATED ART | KURODA KAZUYOSHI | 2011-02-24 | — | — | US | disclosed |
| US-20110045397-A1 | CHARGE CONTROL AGENT AND RELATED ART | KURODA KAZUYOSHI | 2011-02-24 | — | — | US | disclosed |
| US-20090053641-A1 | CHARGE CONTROL AGENT AND RELATED ART | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090053641-A1 | CHARGE CONTROL AGENT AND RELATED ART | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1862860-A1 | CHARGE CONTROL AGENT AND RELATED TECHNIQUE | Orient Chemical Industries, Ltd. (JP) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106312-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | ABCB1, CYP3A5, CYP3A7 | ALOX15 809/4885STS 359/4885TNKS 1737/4885 |
| US-20090053641-A1 | CHARGE CONTROL AGENT AND RELATED ART | H1-4, CECR2, DOT1L | ALOX15 2125/4885STS 4681/4885TNKS 561/4885 |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | ALOX15 1021/4885STS 1342/4885TNKS 4153/4885 |
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ABCB1, CYP3A5, CYP3A7 | ALOX15 809/4885STS 359/4885TNKS 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.